drugset / Trial / NCT01440764

Aerosol Inhalation Treatment for Dyspnea

NCT01440764

RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of this protocol is to develop and test optimal delivery of aerosol furosemide, a treatment that has the potential to significantly improve symptom management and enhance the quality of care for patients with intractable dyspnea.

Timeline

Start
2011-09
Primary completion
2016-04
Completion
2017-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Furosemide Other / unclassified 15 mg Inhaled
Subject Furosemide Other / unclassified 40 mg Inhaled
Subject Furosemide Other / unclassified 80 mg Inhaled

Indications

No indication recorded.